Navigation Links
NUS researchers make new discovery of protein as a promising target for treatment of ATC
Date:2/18/2014

Anaplastic thyroid carcinoma (ATC) is an aggressive type of cancer with a poor prognosis for which there is currently no effective treatment. Researchers from the National University of Singapore (NUS) have discovered for the first time that an epithelial basement membrane protein, called laminin-5 gamma-2 (LAMC2), has the potential to be an ideal target for the treatment of ATC.

Led by Professor H. Phillip Koeffler, Senior Principal Investigator, and Dr Manoj Garg, Research Fellow, at the Cancer Science Institute of Singapore (CSI Singapore) at NUS, the team is also the first to demonstrate that effect of LAMC2 on cell growth, cell cycle, migration and invasion in ATC cells. This novel study was published in the Journal of Clinical Endocrinology and Metabolism last month.

Thyroid cancer is the most common cancer of the endocrine system. ATC are undifferentiated tumours of the thyroid follicular epithelium. This type of cancer has a poor prognosis due to their extremely aggressive nature and resistance to treatment. Overall survival from diagnosis is typically six months or less. As such, new therapeutic targets are needed to improve the clinical care of these patients.

The effect of LAMC2 on ATC cells

In their study, the researchers found that LAMC2 is over-expressed in a large cohort of ATC patient samples. Analysis of RNA data of ATC cells showed that LAMC2 is likely to play a role in the formation of tumours. They discovered that silencing of LAMC2 in ATC cells reduced their cell growth, migration and invasion. In addition, silencing of this protein impaired the cell cycle of ATC cells by arresting them at the growth phase to DNA replication phase, or the G1 to S phase transition, of their cell cycle.

At the same time, the study found that LAMC2 enhanced activation of growth signals through a cell surface protein called epidermal growth factor receptor (EGFR) in ATC cells. EGFR plays an important role in the behaviour of malignant cells in a variety of human tumours by increasing proliferation. Increased expression of epidermal growth factor and EGFR has been detected in 58 per cent to 87 per cent of ATC when compared with normal tissue. The researchers demonstrated that simultaneous silencing of LAMC2 combined with various ways of silencing EGFR effectively inhibited the growth of tumour cells.

The novel study provides a foundation for further investigation of LAMC2 as a promising target for developing novel therapeutic approaches for the treatment of ATC.

Said Prof Koeffler, "Our findings provide a novel target for therapeutic research. We are now extending these investigations to additional types of frequent cancer subtypes."


'/>"/>

Contact: Kimberley Wang
kimberley.wang@nus.edu.sg
National University of Singapore
Source:Eurekalert

Related medicine news :

1. Scripps researchers recommend mobile compression device to prevent DVT after joint surgery
2. No such thing as porn addiction, researchers say
3. LA BioMed researchers report on promising new therapy for devastating genetic disorder
4. NIH-funded researchers use antibody treatment to protect humanized mice from HIV
5. Researchers blend orthopedics, engineering to better repair torn rotator cuffs
6. Researchers discover new hormone receptors to target when treating breast cancer
7. Kessler Foundation MS researchers study predictors of employment status
8. RI Hospital researchers identify components in C. diff that may lead to better treatment
9. Researchers create database to examine vast resources of health legacy foundations
10. UC Irvine stem cell researchers awarded $1.54 million in state funding
11. Researchers find novel approach for controlling deadly C. difficile infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina Group ... New York was founded by James M. Maisel, MD and has been providing tertiary medical ... always followed a legacy of surpassing expectations amongst her peers. Growing up in a ...
(Date:12/5/2016)... (PRWEB) , ... December 05, ... ... professional calibrations is an excellent way to ensure moisture measurements are consistently ... time-consuming and impractical. , Now, METTLER TOLEDO offers a solution: ...
(Date:12/5/2016)... ... 05, 2016 , ... A newly released study has found ... and accuracy of placing precordial electrodes with little cognitive effort and a high ... years, studies have shown that single electrode misplacement is one of the single ...
(Date:12/4/2016)... California (PRWEB) , ... December 03, 2016 , ... ... lower thirds, 4 transitions and many more tools allowing FCPX editors to create ... of Pixel Film Studios. , Perfect Harmony contains a beautifully designed 3D ...
(Date:12/4/2016)... Dallas, TX (PRWEB) , ... December 03, 2016 ... ... of the “Fastest growing Entrepreneurial Company in the Dallas area” Tuesday evening at ... the Omni Dallas Hotel, presented by SMU's Cox School’s Caruth Institute for Entrepreneurship. ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 2016 Sanovas, Inc., a life science ... launch of its wholly owned subsidiary, Intubation Science, Inc., and ...   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal ...
(Date:12/5/2016)... , Dec. 5, 2016  Recently Zymo ... methylation age predictor, known as Horvath,s Clock. Based ... a sample analysis service to academic and biopharma ... any human sample, other than sperm. The ... accurately estimate biological age versus chronological age following ...
(Date:12/5/2016)... Dec. 5, 2016  BD (Becton, Dickinson and Company) ... technology company, will demonstrate an enhanced technology platform designed ... including the company,s leading Pyxis™ and Alaris™ systems, at ... 2016 Midyear Meeting being held in ... While national data show that approximately 68 percent of ...
Breaking Medicine Technology: